Journal article icon

Journal article

Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study

Abstract:
Background: Whether granulocytes for transfusion are beneficial remains uncertain, although some evidence suggests that efficacy may be dose‐related. Granulocytes are mostly produced by apheresis procedure, but other means of production are increasingly used. Methods: Centers that produce and/or use granulocytes were recruited through the BEST Collaborative and completed a detailed survey of granulocyte manufacture, specifications, clinical use, operational considerations, and data collection initiatives. Results: Fifteen national, regional, and local producers and/or users of granulocytes were included. Granulocytes were produced from apheresis procedure (n = 10), pooled buffy coats (n = 2), single buffy coats (n = 4) or pooling of residual leukocyte units from whole blood processing (n = 1). The mean adult dose of granulocytes reported was 1.6 to 3.7 × 1010 for apheresis, and 1.8 to 2.2 × 1010 for pooled buffy coat granulocytes. For apheresis procedure donations, donor stimulation included steroids and/or granulocyte colony‐stimulating factor. Centers providing whole blood‐derived granulocytes reported shorter times from request to delivery than those using apheresis procedure products. Indications and product selection criteria were similar. The most frequently reported challenges with granulocytes were donor availability for apheresis procedure (n = 7), short shelf life (n = 5) and lack of evidence of efficacy (n = 5). The cost of one unit of apheresis procedure granulocytes ranged from 568 to 7500 PPP‐USD, and for one pooled buffy coat unit was from 2208 to 2822 PPP‐USD. Conclusions: We have highlighted differences in granulocyte production that are relevant for the design and interpretation of much needed international clinical studies.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1111/trf.18263

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-7907-3856


Publisher:
Wiley
Journal:
Transfusion More from this journal
Publication date:
2025-05-15
Acceptance date:
2025-04-08
DOI:
EISSN:
1537-2995
ISSN:
0041-1132


Language:
English
Keywords:
Pubs id:
2124961
Local pid:
pubs:2124961
Source identifiers:
2933832
Deposit date:
2025-05-15
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP